SecBot SecBot
6-K ·Filed May 11, 2026

DRTSW

Alpha Tau Medical Ltd.
BULLISH
Impact 7/10
Horizonmonths Processed6mo ago SEC0001213900-26-054252
Notable filing: 6-K
Actionable Insight ▲ Bullish

The strong early efficacy data is a positive catalyst, but the small sample and need for FDA review to complete enrollment warrant caution. Monitor for completion of the 10-patient pilot and any regulatory updates; the next major catalyst is the interim safety analysis and full enrollment milestone.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$1.02
T+0 close · May 11, 2026 · via day close
Latest settled
+230.39%
T+60 · $3.37
Vs SPY
+226.00%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 11 $1.02entry
  2. T+1 · 6mo ago 0.00%α +0.14% · $1.02
  3. T+5 · 6mo ago 0.00%α +0.09% · $1.02
  4. T+20 · 5mo ago 0.00%α +0.30% · $1.02
  5. T+60 · 3mo ago +230.39%α +226.00% · $3.37
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Alpha Tau presented interim data from its REGAIN trial of Alpha DaRT for recurrent glioblastoma (GBM). Of the first three patients treated, two achieved complete responses and one stable disease with a 30% tumor reduction, with no unanticipated side effects. This is a strong early efficacy signal in a difficult-to-treat indication, though the sample is small and further enrollment and FDA review are pending.

Key Facts

  • 3 patients treated in REGAIN trial for recurrent GBM
  • 2 complete responses and 1 stable disease (30% size reduction) as of May 3, 2026
  • No unanticipated side effects; grade 2-3 seizures occurred in 2 patients but resolved to baseline
  • Plan to enroll 10 patients total pending FDA interim safety review
  • Alpha DaRT uses diffusing alpha-emitters radiotherapy delivered via stereotactic implantation

Financial Impact

Pre-revenue company; no financial data provided

Risk Factors

  • Small sample size (n=3) limits statistical reliability
  • Two patients experienced grade 2-3 seizures, though manageable
  • Regulatory and clinical risks: FDA may require additional data before allowing full enrollment

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-054252
Document: ea0290058-6k_alpha.htm0001213900-26-054252
Document: 0001213900-26-054252-index-headers.html0001213900-26-054252
Document: 0001213900-26-054252-index.html0001213900-26-054252
Document: 0001213900-26-054252.txt0001213900-26-054252

Track record

14 reports on DRTSW

Performance horizon

8 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +292.16% at T+60 after the Jun 3, 2026 report. 8 of 8 went positive at some point.

Filters
  1. Jun 3, 202623w ago 6-K Bullish 7/10 Entry $1.02 to $4.00 ▲ +292.16% +289.66% vs SPY
  2. Jun 1, 202624w ago 6-K Bullish 7/10 Entry $1.02 to $3.89 ▲ +281.37% +280.14% vs SPY
  3. May 18, 202626w ago 6-K Neutral 5/10 Entry $1.02 to $3.89 ▲ +281.37% +275.08% vs SPY
  4. May 11, 202627w ago 6-K Bullish 7/10 Viewing Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  5. May 11, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.37 ▲ +230.39% +226.00% vs SPY
  6. May 8, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  7. May 8, 202627w ago 6-K Bullish 6/10 Entry $1.02 to $3.30 ▲ +223.53% +218.69% vs SPY
  8. May 7, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.58 ▲ +152.94% +149.11% vs SPY
  9. May 5, 202627w ago 6-K Neutral 3/10 Entry $1.02 to $2.70 ▲ +164.71% +161.97% vs SPY
  10. May 4, 202628w ago 6-K Bullish 7/10 Entry $1.02 to $2.29 ▲ +124.51% +122.65% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 8h 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 11, 2026